{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:46:12Z","timestamp":1793951172402,"version":"4.8.0"},"reference-count":151,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondation L\u00e9on Fredericq","award":["FHULF\/MEL\/2023-2024"],"award-info":[{"award-number":["FHULF\/MEL\/2023-2024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Opportunistic viral infections of the central nervous system represent a significant cause of morbidity and mortality among an increasing number of immunocompromised patients. Since antiviral treatments are usually poorly effective, the prognosis generally relies on the ability to achieve timely immune reconstitution. Hence, strategies aimed at reinvigorating antiviral immune activity have recently emerged. Among these, virus-specific T-cells are increasingly perceived as a principled and valuable tool to treat opportunistic viral infections. Here we briefly discuss how to develop and select virus-specific T-cells, then review their main indications in central nervous system infections, including progressive multifocal leukoencephalopathy, CMV infection, and adenovirus infection. We also discuss their potential interest in the treatment of progressive multiple sclerosis, or EBV-associated central nervous system inflammatory disease. We finish with the key future milestones of this promising treatment strategy.<\/jats:p>","DOI":"10.3390\/v15071510","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T01:41:36Z","timestamp":1688694096000},"page":"1510","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Nicolas","family":"Lambert","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital of Li\u00e8ge, 4000 Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2560-5199","authenticated-orcid":false,"given":"Majdouline","family":"El Moussaoui","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine and Infectious Diseases, University Hospital of Li\u00e8ge, 4000 Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Li\u00e8ge, 4000 Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Maquet","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of Li\u00e8ge, 4000 Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-1351","authenticated-orcid":false,"given":"Gilles","family":"Darcis","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine and Infectious Diseases, University Hospital of Li\u00e8ge, 4000 Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11910-021-01119-w","article-title":"Central Nervous System Infections in Immunocompromised Patients","volume":"21","author":"Pruitt","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MCC.0000000000000397","article-title":"Central nervous system infections in immunocompromised patients","volume":"23","author":"Sonneville","year":"2017","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awac237","article-title":"Progressive multifocal leukoencephalopathy: Epidemiology and spectrum of predisposing conditions","volume":"146","author":"Joly","year":"2023","journal-title":"Brain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ana.23988","article-title":"Novel approaches and challenges to treatment of central nervous system viral infections","volume":"74","author":"Nath","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1111\/ene.15021","article-title":"Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: Identifying relevant outcome factors","volume":"28","author":"Lambert","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"805657","DOI":"10.3389\/fimmu.2022.805657","article-title":"How Does the Immune System Enter the Brain?","volume":"13","author":"Mapunda","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-065X.2012.01140.x","article-title":"T-cell trafficking in the central nervous system","volume":"248","author":"Sallusto","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nri.2016.144","article-title":"T cell responses in the central nervous system","volume":"17","author":"Korn","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14712590903456003","article-title":"Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation","volume":"10","author":"Leen","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","article-title":"The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells","volume":"128","author":"Riddell","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood.V97.4.994","article-title":"Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: A novel culture system free of live CMV virions","volume":"97","author":"Peggs","year":"2001","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1073\/pnas.92.6.1921","article-title":"Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix","volume":"92","author":"Manz","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.0.CO;2-C","article-title":"Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion","volume":"29","author":"Brosterhus","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/14712598.2021.1857720","article-title":"Cell therapy for cytomegalovirus infection","volume":"21","author":"Neill","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-3-319-22834-1_15","article-title":"Adoptive T-Cell Immunotherapy","volume":"Volume 391","author":"Gottschalk","year":"2015","journal-title":"Epstein Barr Virus Volume 2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.20.02608","article-title":"Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation","volume":"39","author":"Olson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"211","article-title":"Cell and Gene Therapy for HIV Cure","volume":"417","author":"Peterson","year":"2018","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/imm.13262","article-title":"T-cell responses and therapies against SARS-CoV-2 infection","volume":"162","author":"Toor","year":"2021","journal-title":"Immunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CJI.0b013e318181b4bd","article-title":"Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy","volume":"31","author":"Fujita","year":"2008","journal-title":"J. Immunother."},{"key":"ref_25","first-page":"2736","article-title":"Generation of multivirus-specific T cells to prevent\/treat viral infections after allogeneic hematopoietic stem cell transplant","volume":"51","author":"Gerdemann","year":"2011","journal-title":"J. Vis. Exp."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CJI.0000000000000197","article-title":"Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation","volume":"41","author":"Kassa","year":"2018","journal-title":"J. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.26512","article-title":"Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors","volume":"93","author":"Boumaza","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3201\/eid2801.204809","article-title":"Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy","volume":"28","author":"Lambert","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"889148","DOI":"10.3389\/fimmu.2022.889148","article-title":"Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy with Atezolizumab, A Case Report","volume":"13","author":"Lambert","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ana.26307","article-title":"Outcome of Progressive Multifocal Leukoencephalopathy Treated by Interleukin-7","volume":"91","author":"Lajaunie","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00415-021-10952-5","article-title":"Innovative therapeutic concepts of progressive multifocal leukoencephalopathy","volume":"269","author":"Hopfner","year":"2022","journal-title":"J. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/bmt.2010.221","article-title":"Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient","volume":"46","author":"Balduzzi","year":"2011","journal-title":"Bone Marrow Transpl."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11170","DOI":"10.1128\/JVI.79.17.11170-11178.2005","article-title":"Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides","volume":"79","author":"Krymskaya","year":"2005","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13094","DOI":"10.1128\/JVI.79.20.13094-13104.2005","article-title":"Complete nucleotide sequence of polyomavirus SA12","volume":"79","author":"Cantalupo","year":"2005","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1099\/vir.0.82094-0","article-title":"T-cell responses to peptide fragments of the BK virus T antigen: Implications for cross-reactivity of immune response to JC virus","volume":"87","author":"Li","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4049\/jimmunol.168.1.499","article-title":"Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope","volume":"168","author":"Koralnik","year":"2002","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1474-4422(21)00174-5","article-title":"BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: An open-label, single-cohort pilot study","volume":"20","author":"Cortese","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ana.26020","article-title":"Adoptive Transfer of JC Virus-Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy","volume":"89","author":"Berzero","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1042","DOI":"10.1212\/NXI.0000000000001042","article-title":"Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report","volume":"8","author":"Wicklein","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1212\/NXI.0000000000001020","article-title":"Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy","volume":"8","author":"Hopfner","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12967-020-02337-5","article-title":"Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes","volume":"18","author":"Steinhardt","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2021.11.005","article-title":"Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients","volume":"28","author":"Rubinstein","year":"2022","journal-title":"Transpl. Cell Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.healun.2022.04.001","article-title":"Successful JC virus-targeted T-cell therapy for progressive multifocal leukoencephalopathy in a lung transplant recipient","volume":"41","author":"Peghin","year":"2022","journal-title":"J. Heart Lung Transpl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.21037\/jtd.2016.03.29","article-title":"Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China","volume":"8","author":"Tian","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/1873-3468.13576","article-title":"Adenovirus persistence, reactivation, and clinical management","volume":"593","author":"Lion","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bbmt.2018.12.753","article-title":"Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplantation Recipients: Findings from the Advance Study","volume":"25","author":"Petterson","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cesaro, S., and Porta, F. (2022). Adenovirus Infection in Pediatric Hematopoietic Cell Transplantation: A Challenge Still Open for Survival. J. Clin. Med., 11.","DOI":"10.20944\/preprints202207.0251.v1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1086\/319352","article-title":"Adenovirus infections in adult recipients of blood and marrow transplants","volume":"32","author":"Champlin","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2018.09.036","article-title":"Adenovirus-Associated Central Nervous System Disease in Children","volume":"205","author":"Schwartz","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_55","first-page":"5528198","article-title":"An Adult Case of Adenovirus-Associated Acute Disseminated Encephalomyelitis","volume":"2023","author":"Campbell","year":"2023","journal-title":"Case Rep. Infect Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jcv.2013.03.017","article-title":"Adenovirus infection associated with central nervous system dysfunction in children","volume":"57","author":"Huang","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/14787210.2013.836964","article-title":"Diagnosis and treatment of adenovirus infection in immunocompromised patients","volume":"11","author":"Boztug","year":"2013","journal-title":"Expert Rev. Anti. Infect Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.2005.05649.x","article-title":"Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation","volume":"130","author":"Kampmann","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1980","DOI":"10.1002\/rmv.1980","article-title":"Management of adenovirus infection in patients after haematopoietic stem cell transplantation: State-of-the-art and real-life current approach: A position statement on behalf of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation","volume":"28","author":"Hiwarkar","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MOT.0000000000000542","article-title":"Adenovirus infection in pediatric transplant recipients: Are effective antiviral agents coming our way?","volume":"23","author":"Lopez","year":"2018","journal-title":"Curr. Opin. Organ Transpl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40265-013-0007-5","article-title":"Acute viral infections of the central nervous system in immunocompetent adults: Diagnosis and management","volume":"73","author":"Studahl","year":"2013","journal-title":"Drugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood.2019004315","article-title":"Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT","volume":"135","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"ref_64","first-page":"663","article-title":"Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation","volume":"14","author":"Hromas","year":"1994","journal-title":"Bone Marrow Transpl."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1086\/313514","article-title":"Adenovirus infections in hematopoietic stem cell transplant recipients","volume":"29","author":"Howard","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2002-02-0377","article-title":"Adenovirus infections following allogeneic stem cell transplantation: Incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery","volume":"100","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2141.2004.05218.x","article-title":"Adenovirus as an emerging pathogen in immunocompromised patients","volume":"128","author":"Leen","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2003.12.009","article-title":"Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy","volume":"32","author":"Feuchtinger","year":"2004","journal-title":"Exp. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after, HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-017-0469-0","article-title":"Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: A successful phase I\/II multicenter clinical trial","volume":"10","author":"Qian","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","article-title":"Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted","volume":"5","author":"Rubinstein","year":"2021","journal-title":"Blood Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jcyt.2018.03.040","article-title":"Multicenter phase 1\/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation","volume":"20","author":"Ip","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaci.2016.03.032","article-title":"Specific T cells for the treatment of cytomegalovirus and\/or adenovirus in the context of hematopoietic stem cell transplantation","volume":"138","author":"Creidy","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients","volume":"9","author":"Humar","year":"2009","journal-title":"Am. J. Transpl."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/blood-2005-03-1039","article-title":"Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation","volume":"107","author":"Cook","year":"2006","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/QAD.0b013e32835b0fa2","article-title":"Declining incidence of AIDS-defining opportunistic illnesses: Results from 16 years of population-based AIDS surveillance","volume":"27","author":"Schwarcz","year":"2013","journal-title":"AIDS"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/00002030-199611000-00009","article-title":"Cytomegalovirus retinitis in AIDS patients: Influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival","volume":"10","author":"Bowen","year":"1996","journal-title":"AIDS"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","article-title":"Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation","volume":"7","author":"Xie","year":"2023","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/tri.12659","article-title":"Virus-specific T-cell therapy in solid organ transplantation","volume":"29","author":"Roemhild","year":"2016","journal-title":"Transpl. Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/bmt.2010.35","article-title":"CMV central nervous system disease in stem-cell transplant recipients: An increasing complication of drug-resistant CMV infection and protracted immunodeficiency","volume":"45","author":"Reddy","year":"2010","journal-title":"Bone Marrow Transpl."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00023210-200216050-00003","article-title":"CNS manifestations of cytomegalovirus infections: Diagnosis and treatment","volume":"16","author":"Maschke","year":"2002","journal-title":"CNS Drugs"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3324\/haematol.2010.029876","article-title":"Viralence-phalitis after allogeneic stem cell transplantation: A rare complication with distinct characteristics of different causative agents","volume":"96","author":"Schwender","year":"2011","journal-title":"Haematologica"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Chen, S.J., Wang, S.C., and Chen, Y.C. (2019). Antiviral Agents as Therapeutic Strategies Against Cytomegalovirus Infections. Viruses, 12.","DOI":"10.3390\/v12010021"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jns.2018.02.029","article-title":"Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature","volume":"15","author":"Baghban","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e00043-19","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2040620720937150","DOI":"10.1177\/2040620720937150","article-title":"Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant","volume":"11","author":"Shigle","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: A French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ouellette, C.P. (2022). Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection. Viruses, 14.","DOI":"10.3390\/v14112370"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ajh.26535","article-title":"Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy","volume":"97","author":"Pei","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41409-021-01499-0","article-title":"Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation","volume":"57","author":"Wang","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e165476","DOI":"10.1172\/JCI165476","article-title":"Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant","volume":"133","author":"Prockop","year":"2023","journal-title":"J. Clin. Invest."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e13584","DOI":"10.1111\/petr.13584","article-title":"Successful treatment of post-transplant CMV meningoencephalitis with third-party CMV virus-specific T cells: Lessons learned","volume":"23","author":"Alonso","year":"2019","journal-title":"Pediatr. Transpl."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/16078454.2019.1710945","article-title":"Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Ke","year":"2020","journal-title":"Hematology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2249.2003.02098.x","article-title":"Cellular responses to cytomegalovirus in immunosuppressed patients: Circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment","volume":"132","author":"Engstrand","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein-Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The Global Landscape of EBV-Associated Tumors","volume":"9","author":"Rickinson","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1002\/cti2.1444","article-title":"Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis","volume":"12","author":"Smith","year":"2023","journal-title":"Clin. Transl. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.coviro.2013.04.005","article-title":"The pathogenesis of Epstein-Barr virus persistent infection","volume":"3","author":"Hawkins","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., and Yamanishi, K. (2007). Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge University Press.","DOI":"10.1017\/CBO9780511545313"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJM198910193211604","article-title":"Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease","volume":"321","author":"Young","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Ann. Rev. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.micro.54.1.19","article-title":"Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases","volume":"54","author":"Khanna","year":"2000","journal-title":"Ann. Rev. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/JVI.00239-09","article-title":"Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression","volume":"83","author":"Smith","year":"2009","journal-title":"J. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1093\/brain\/awq223","article-title":"Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: What you find depends on how and where you look","volume":"133","author":"Aloisi","year":"2010","journal-title":"Brain"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/NEN.0b013e31827bfc62","article-title":"B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis","volume":"72","author":"Magliozzi","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/NEN.0b013e3181e332ec","article-title":"Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: Implications for viral persistence and intrathecal B-cell activation","volume":"69","author":"Serafini","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Hassani, A., Corboy, J.R., Al-Salam, S., and Khan, G. (2018). Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192109"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1212\/NXI.0000000000000466","article-title":"Molecular signature of Epstein-Barr virus infection in MS brain lesions","volume":"5","author":"Moreno","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.molmed.2021.01.004","article-title":"Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies","volume":"27","author":"Pender","year":"2021","journal-title":"Trends Mol. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2217\/imt.14.43","article-title":"Epstein-Barr virus-specific adoptive immunotherapy: A new horizon for multiple sclerosis treatment?","volume":"6","author":"Pender","year":"2014","journal-title":"Immunotherapy"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.4049\/jimmunol.177.7.4897","article-title":"Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope","volume":"177","author":"Smith","year":"2006","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1038\/cti.2014.31","article-title":"Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement","volume":"4","author":"Smith","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e124714","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e1273311","DOI":"10.1080\/2162402X.2016.1273311","article-title":"Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response","volume":"6","author":"Smith","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458514521888","article-title":"Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis","volume":"20","author":"Pender","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"652811","DOI":"10.3389\/fneur.2021.652811","article-title":"Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein-Barr Virus-Specific T Cell Therapy","volume":"12","author":"Ioannides","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_131","first-page":"72","article-title":"Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis","volume":"28","author":"Pender","year":"2022","journal-title":"Mult. Scler. J."},{"key":"ref_132","first-page":"120","article-title":"Adverse Effects of Virus-Specific T-Cell Therapy: An Integrative Review","volume":"10","author":"Simmons","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/14653241003709686","article-title":"Adverse events following infusion of T cells for adoptive immunotherapy: A 10-year experience","volume":"12","author":"Cruz","year":"2010","journal-title":"Cytotherapy"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virusrelated lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-Specific T Cells for the Immunocompromised Patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/mt.2014.192","article-title":"Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells","volume":"23","author":"Melenhorst","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.bbmt.2010.12.711","article-title":"Alloreactivity across HLA barriers is mediated by both na\u00efve and antigen-experienced T cells","volume":"17","author":"Melenhorst","year":"2011","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fimmu.2013.00330","article-title":"Alloreactivity of virus-specific T cells: Possible implication of graft-versus-host disease and graft-versus-leukemia effects","volume":"4","author":"Fuji","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CJI.0000000000000031","article-title":"T-cell therapy using a bank of EBV-specific cytotoxic T cells: Lessons from a phase I\/II feasibility and safety study","volume":"37","author":"Gallot","year":"2014","journal-title":"J. Immunother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","article-title":"Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor","volume":"31","author":"Foster","year":"2008","journal-title":"J. Immunother."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2015-08-664755","article-title":"TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells","volume":"126","author":"Menger","year":"2015","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1111\/ajt.12475","article-title":"Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy","volume":"13","author":"Ricciardelli","year":"2013","journal-title":"Am. J. Transpl."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1182\/blood-2009-07-230482","article-title":"Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)","volume":"114","author":"Dotti","year":"2009","journal-title":"Blood"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1510\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:07:05Z","timestamp":1760126825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":151,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["v15071510"],"URL":"https:\/\/doi.org\/10.3390\/v15071510","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}